Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Key player in Pershing Square's Valeant bet leaving firm

Published 05/11/2016, 05:03 PM
Updated 05/11/2016, 05:03 PM
Key player in Pershing Square's Valeant bet leaving firm

Key player in Pershing Square's Valeant bet leaving firm

By Svea Herbst-Bayliss

LAS VEGAS (Reuters) - William Doyle, a key figure in Pershing Square (NYSE:SQ) Capital Management's controversial investment in battered drug company Valeant Pharmaceuticals (NYSE:VRX), is leaving the hedge fund, its founder, William Ackman, told investors on Wednesday.

Doyle joined Pershing Square's investment team in October 2014, but had also been involved in other projects including advising cancer therapy company Novocure, which listed its stock last year.

"The demands of overseeing Novocure and managing its relationship with shareholders and other stakeholders have made it infeasible for Bill to continue as a member of the investment team," Ackman wrote in a letter to investors that was seen by Reuters.

Novocure said on Wednesday that Doyle will be the company's executive chairman after having already been a board member. Ackman said Doyle will also spend time at Table Management, an entity that oversees private investments for Ackman's family, Ackman wrote in his letter.

Doyle introduced Michael Pearson (LON:PSON), the former CEO of Valeant, and Ackman, the billionaire activist investor, in early 2014 and a year later Ackman's Pershing Square invested in the Canadian drugmaker.

In 2015, Ackman called Valeant his best idea but it has become the firm's biggest ever loser. Valeant's stock has tumbled 85 percent amid scrutiny over its accounting and pricing practices, ultimately prompting Ackman to join Valeant's board and forcing Pearson to leave his position as CEO.

Doyle was friends with Pearson from their days as consultants at McKinsey and Doyle knew Ackman through Harvard Business School. Doyle joined Pershing Square's investment team shortly after brokering the initial meeting and helped oversee science-oriented investments.

Last month, Pershing Square said Doyle would not stand for reelection as a board member at animal health company Zoetis Inc (NYSE:ZTS). Earlier this week the fund sold a chunk of its investment in the company.

Doyle's exit marks the second departure of a Pershing Square investment team member in five months. In January, Paul Hilal, who has been friends with Ackman since college, left the firm.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.